Infections due to Carbapenem Resistant Enterobacteriaceae among Saudi Arabian Hospitalized Patients: A Matched Case-Control Study

BioMed Research International

Volumn 2016, Issue , 2016, Pages

  Garbati, M A ^a   Sakkijha, H ^a   Abushaheen, A ^a  

^a KING FAHAD MEDICAL CITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CARBAPENEM; CEPHALOSPORIN; CIPROFLOXACIN; COLISTIN; CORTICOSTEROID; IMIPENEM; MEROPENEM; METRONIDAZOLE; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE; TIGECYCLINE; VANCOMYCIN; CARBAPENEM DERIVATIVE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CARBAPENEM SUSCEPTIBLE ENTEROBACTERIACEAE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CENTRAL VENOUS CATHETERIZATION; CHARLSON COMORBIDITY INDEX; CITROBACTER; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; ENTEROBACTER; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; FEMALE; HEALTHCARE ASSOCIATED INFECTION; HOSPITAL ADMISSION; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; INFECTION RISK; INTENSIVE CARE UNIT; INVASIVE PROCEDURE; KIDNEY DISEASE; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; LIVER DISEASE; LUNG DISEASE; MALE; MALIGNANT NEOPLASTIC DISEASE; MIDDLE AGED; MONOTHERAPY; MORTALITY; NEUROLOGIC DISEASE; NONHUMAN; RENAL REPLACEMENT THERAPY; SAUDI; SAUDI ARABIA; SURGERY; TREATMENT OUTCOME; VERY ELDERLY; CLASSIFICATION; CROSS INFECTION; DRUG EFFECTS; ENTEROBACTERIACEAE INFECTIONS; EPIDEMIOLOGY; HOSPITALIZATION; INCIDENCE; ISOLATION AND PURIFICATION; MICROBIOLOGY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARBAPENEMS; CASE-CONTROL STUDIES; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RISK FACTORS; SAUDI ARABIA; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84965098207     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2016/3961684     Document Type: Article

References (43)

1. K. M. Papp-Wallace, A. Endimiani, M. A. Taracila, and R. A. Bonomo, "Carbapenems: past, present, and future, " Antimicrobial Agents and Chemotherapy, vol. 55, no. 11, pp. 4943-4960, 2011.
2. K. Z. Vardakas, D. K. Matthaiou, M. E. Falagas, E. Antypa, A. Koteli, and E. Antoniadou, "Characteristics, risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in the intensive care unit, " Journal of Infection, vol. 70, no. 6, pp. 592-599, 2015.
3. M. Souli, I. Galani, A. Antoniadou et al., "An outbreak of infection due to lactamase Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in a Greek university hospital: Molecular characterization, epidemiology, and outcomes, " Clinical Infectious Diseases, vol. 50, no. 3, pp. 364-373, 2010.
4. F. Baquero, M. C. Negri, M. I. Morosini, and J. Blázquez, "Antibiotic Selective environments, " Clinical Infectious Diseases, vol. 27, supplement 1, pp. S5-S11, 1998.
5. Centers for Disease Control and Prevention (CDC), "Vital signs: carbapenem-resistant Enterobacteriaceae, "Morbidity and MortalityWeekly Report, vol. 62, no. 9, pp. 165-170, 2013.
6. W. C. Rottier, H. S. M. Ammerlaan, and M. J. M. Bonten, "Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrumlactamase-producing Enterobacteriaceae and patient outcome: A meta-analysis, " Journal of Antimicrobial Chemotherapy, vol. 67, no. 6, pp. 1311-1320, 2012.
7. G. Patel, S. Huprikar, S. H. Factor, S. G. Jenkins, and P. Calfee, "Outcomes of carbapenem resistant Klebsiella pneumoniae infection and impact of antimicrobial and adjunctive therapies, " Infection Control & Hospital Epidemiology, vol. 29, pp. 1099-1106, 2008.
8. M. E. Falagas, P. I. Rafailidis, D. Kofteridis et al., "Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: A matched case-Control study, " Journal of Antimicrobial Chemotherapy, vol. 60, no. 5, pp. 1124-1130, 2007.
9. A. Borer, L. Saidel-Odes, K. Riesenberg et al., "Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia, " Infection Control and Hospital Epidemiology, vol. 30, no. 10, pp. 972-976, 2009.
10. C. J. Gregory, E. Llata, N. Stine et al., "Outbreak of carbapenemresistant Klebsiella pneumoniae in Puerto Rico associated with a novel carbapenemase variant, " Infection Control and Hospital Epidemiology, vol. 31, no. 5, pp. 476-484, 2010.
11. K. Hussein, H. Sprecher, T. Mashiach, I. Oren, I. Kassis, and R. Finkelstein, "Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns, " Infection Control and Hospital Epidemiology, vol. 30, no. 7, pp. 666-671, 2009.
12. K. Hussein, A. Raz-Pasteur, R. Finkelstein et al., "Impact of carbapenem resistance on the outcome of patients' hospitalacquired bacteraemia caused by Klebsiella pneumoniae, " Journal of Hospital Infection, vol. 83, no. 4, pp. 307-313, 2013.
13. P. Nordmann, T. Naas, and L. Poirel, "Global spread of carbapenemase producing Enterobacteriaceae, "Emerging Infectious Diseases, vol. 17, no. 10, pp. 1791-1798, 2011.
14. R. Cantón, M. Akóva, Y. Carmeli et al., "Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe, " Clinical Microbiology and Infection, vol. 18, no. 5, pp. 413-431, 2012.
15. M. A. Garbati, A. Bin Abdulhak, K. Baba, and H. Sakkijha, "Infection due to colistin-resistant Enterobacteriacae in critically-ill patients, " Journal of Infection in Developing Countries, vol. 7, no. 10, pp. 713-719, 2013.
16. T. Tängdén and C. G. Giske, "Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control, " Journal of Internal Medicine, vol. 277, no. 5, pp. 501-512, 2015.
17. S. Vergara-López, M. C. Domýnguez, M. C. Conejo, A. Pascual, and J. Rodrýguez-Baño, "Lessons from an outbreak of metallo-.-lactamase-producing Klebsiella oxytoca in an intensive care unit: the importance of time at risk and combination therapy, " The Journal of Hospital Infection, vol. 89, no. 2, pp. 123-131, 2015.
18. Clinical and Laboratory Standard Institute, "Performance standard for antimicrobial susceptibility testing: twenty-second informational supplement, " Tech. Rep. M100-S23, CLSI, Wayne, Pa, USA, 2013.
19. United States Food and Drug Administration (FDA), "Highlights of prescribing information Tygacil, " 2014, http://www. fda. gov/safety/medwatch/safetyinformation/safety-relateddruglabelingchanges/ ucm132714.
20. EUCAST, January 2012, http://www. eucast. org/fileadmin/src/ media/PDFs/EUCAST files/Disk test documents/EUCAST breakpoints v 2. 0 111130. pdf.
21. M. E. Charlson, P. Pompei, K. L. Ales, and C. R. MacKenzie, "A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, " Journal of Chronic Diseases, vol. 40, no. 5, pp. 373-383, 1987.
22. H. H. Balkhy, A. El-Saed, S. M. Al Johani et al., "The epidemiology of the first described carbapenem-resistant Klebsiella pneumoniae outbreak in a tertiary care hospital in Saudi Arabia: How far do we go" European Journal of ClinicalMicrobiology& Infectious Diseases, vol. 31, no. 8, pp. 1901-1909, 2012.
23. A. Shibl, M. Al-Agamy, Z. Memish, A. Senok, S. A. Khader, and A. Assiri, "The emergence ofOXA-48-andNDM-1-positive Klebsiella pneumoniae in Riyadh, Saudi Arabia, " International Journal of Infectious Diseases, vol. 17, no. 12, pp. e1130-e1133, 2013.
24. M. Swaminathan, S. Sharma, S. P. Blash et al., "Prevalence and risk factors for acquisition of carbapenem-resistant Enterobacteriaceae in the setting of endemicity, " Infection Control and Hospital Epidemiology, vol. 34, no. 8, pp. 809-817, 2013.
25. M.-H. Jeon, S.-H. Choi, Y. G. Kwak et al., "Risk factors for the acquisition of carbapenem-resistant Escherichia coli among hospitalized patients, " Diagnostic Microbiology and Infectious Disease, vol. 62, no. 4, pp. 402-406, 2008.
26. A. S. Chitnis, P. S. Caruthers, A. K. Rao et al., "Outbreak of carbapenem-resistant Enterobacteriaceae at a long-term acute care hospital: sustained reductions in transmission through active surveillance and targeted interventions, " Infection Control and Hospital Epidemiology, vol. 33, no. 10, pp. 984-992, 2012.
27. C.-M. Ho, M.-W. Ho, Y.-C. Liu et al., "Correlation between carbapenem consumption and resistance to carbapenems among Enterobacteriaceae isolates collected from patients with intraabdominal infections at five medical centers in Taiwan, 2006-2010, " International Journal of Antimicrobial Agents, vol. 40, supplement 1, pp. S24-S28, 2012.
28. Z. A. Memish, A. Assiri, M. Almasri et al., "Molecular characterization of carbapenemase production among gram-negative bacteria in Saudi Arabia, " Microbial Drug Resistance, vol. 21, no. 3, pp. 307-314, 2015.
29. H. M. Zowawi, A. L. Sartor, H. H. Balkhy et al., "Molecular characterization of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae in the countries of the gulf cooperation council: dominance of OXA-48 and NDM Producers, " Antimicrobial Agents and Chemotherapy, vol. 58, no. 6, pp. 3085-3090, 2014.
30. Y. Xu, B. Gu, M. Huang et al., "Epidemiology of carbapenem resistant Enterobacteriaceae (CRE) during 2000-2012 in Asia, " Journal ofThoracic Disease, vol. 7, no. 3, pp. 376-385, 2015.
31. M. Castanheira, H. S. Sader, L. M. Deshpande, T. R. Fritsche, and R. N. Jones, "Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase-and metallo-.-lactamase-producing Enterobacteriaceae: report from the SENTRY antimicrobial surveillance program, " Antimicrobial Agents and Chemotherapy, vol. 52, no. 2, pp. 570-573, 2008.
32. D. M. Livermore, M. Warner, S. Mushtaq, M. Doumith, J. Zhang, and N. Woodford, "What remains against carbapenemresistant Enterobacteriaceae Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline, " International Journal of Antimicrobial Agents, vol. 37, no. 5, pp. 415-419, 2011.
33. Z. A. Qureshi, D. L. Paterson, B. A. Potoski et al., "Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens, " AntimicrobialAgents and Chemotherapy, vol. 56, no. 4, pp. 2108-2113, 2012.
34. O. Zarkotou, S. Pournaras, P. Tselioti et al., "Predictors ofmortality in patients with bloodstream infections caused by KPCproducing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment, " Clinical Microbiology and Infection, vol. 17, no. 12, pp. 1798-1803, 2011.
35. E. B. Hirsch and V. H. Tam, "Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): An emerging cause of multidrug-resistant infection, " Journal of Antimicrobial Chemotherapy, vol. 65, no. 6, Article IDdkq108, pp. 1119-1125, 2010.
36. M. Tumbarello, P. Viale, C. Viscoli et al., "Predictorsofmortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy, " Clinical Infectious Diseases, vol. 55, no. 7, pp. 943-950, 2012.
37. F. Sbrana, P. Malacarne, B. Viaggi et al., "Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit, " Clinical Infectious Diseases, vol. 56, no. 5, pp. 697-700, 2013.
38. M. E. Falagas, P. Lourida, P. Poulikakos, P. I. Rafailidis, and G. S. Tansarli, "Antibiotic treatment of infections due to carbapenemresistant Enterobacteriaceae: systematic evaluation of the available evidence, " Antimicrobial Agents and Chemotherapy, vol. 58, no. 2, pp. 654-663, 2014.
39. K. Z. Vardakas, D. K. Matthaiou, M. E. Falagas, E. Antypa, A. Koteli, and E. Antoniadou, "Tigecycline for carbapenemresistant Klebsiella pneumoniae infections in the intensive care unit, " Infectious Diseases, vol. 47, no. 10, pp. 751-753, 2015.
40. S. Pournaras, G. Vrioni, E. Neou et al., "Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay, " International Journal of Antimicrobial Agents, vol. 37, no. 3, pp. 244-247, 2011.
41. A. Antoniadou, F. Kontopidou, G. Poulakou et al., "Colistinresistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of amulticlonal cluster, " Journal of Antimicrobial Chemotherapy, vol. 59, no. 4, pp. 786-790, 2007.
42. D. Marchaim, T. Chopra, J. M. Pogue et al., "Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in Metropolitan Detroit, Michigan, " Antimicrobial Agents and Chemotherapy, vol. 55, no. 2, pp. 593-599, 2011.
43. J. Lee, G. Patel, S. Huprikar, D. P. Calfee, and S. G. Jenkins, "Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection, " Journal of Clinical Microbiology, vol. 47, no. 5, pp. 1611-1612, 2009.